SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (27431)1/16/1999 4:21:00 PM
From: RXGOLF  Read Replies (1) | Respond to of 32384
 
Once again Henry, your review is appreciated! I for one, feel that Lilly should go ahead full speed with Targretin, of course combined with a new and effective drug to lower triglycerides! You can make more money selling two drugs than one ;- ).

Just for clarity, was Targretin not only effective in tx and prevention of breast cancer in the animal model, but found to be much more so than Nolvadex(tamoxifen)was in its animal model?

Thanks,
Greg


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News